Galmed 恢复纳斯达克最低股价合规，解除退市风险

----- form6-k.htm -----
6-K
1
form6-k.htm
6-K
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For
the Month of September 2026
001-36345
(Commission
File Number)
GALMED
PHARMACEUTICALS LTD.
(Exact
name of Registrant as specified in its charter)
c/o
Meitar Law Offices Abba Hillel Silver Rd.,
Ramat
Gan, 5250608
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
On
September 3, 2026, the Nasdaq Listing Qualifications Staff notified Galmed Pharmaceuticals Ltd. (the “Company”) that it had
regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The Company is now in compliance
with all applicable listing standards, and its ordinary shares will continue to be listed and traded on The Nasdaq Stock Market.
The
Company was previously notified by Nasdaq on January 29, 2026 that it had failed to maintain a minimum bid price of $1.00 per share for
30 consecutive trading days, as required by Nasdaq Listing Rule 5550(a)(2), and was provided until July 28, 2026 to regain compliance.
The Company did not regain compliance during the initial 180-calendar-day compliance period and subsequently received an additional 180-calendar-day
compliance period to cure the deficiency.
To
regain compliance with the minimum bid price requirement, the Company was required to maintain a closing bid price of at least $1.00
per share for a minimum of 10 consecutive trading days. From August 20, 2026 through September 2, 2026, the closing bid price of the
Company’s ordinary shares was $1.00 per share or greater for 10 consecutive trading days. As a result, the Company has regained
compliance with Nasdaq Listing Rule 5550(a)(2), and the matter is now closed.
This
Form 6-K is incorporated by reference into the Company’s Registration Statements on Form S-8 (Registration Nos.
333-206292
,
333-227441
,
333-284163
and
333-290399
) and the Company’s Registration Statement on Form F-3 (Registration Nos.
333-272722
and
333-283241
).
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
Galmed
Pharmaceuticals Ltd.
Date:
September 8, 2026
By:
/s/
Allen Baharaff
Allen
Baharaff
President
and Chief Executive Officer